Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer

Published:2007-12 Issue:3 Volume:58 Page:414-417
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Chang John Wen-Cheng,Chou Chun-Liang,Huang Shiu-Feng,Wang Hung-Ming,Hsieh Jia-Juan,Hsu Todd,Cheung Yun-Chung

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference18 articles.

1. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions;Pinkas-Kramarski;EMBO J,1996

2. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

3. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways;Raffaella;Science,2004

4. multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer;Fukuoka;J Clin Oncol,2003

5. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial;Kris;JAMA,2003

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Traditional Chinese Medicine Formulae QY305 Reducing Cutaneous Adverse Reaction and Diarrhea by its Nanostructure;Advanced Science;2023-12-03

2. Retracted : The prognosis analysis of epidermal growth factor receptor tyrosine kinase inhibitor targeted treatment combined with chemotherapy in smokers with nonsmall cell lung cancer;Journal of Cellular Biochemistry;2018-10-28

3. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy;BMC Pharmacology and Toxicology;2017-05-10

4. Plasma T790M and HGF as potential predictive markers for EGFR-TKI re-challenge;Oncology Letters;2017-04-24

5. Poorer prognosis in Taiwanese female ever smokers with stage IV lung adenocarcinoma who were readministered a tyrosine kinase inhibitor;OncoTargets and Therapy;2016-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3